|Day Low/High||1.52 / 1.57|
|52 Wk Low/High||0.66 / 2.75|
Alkermes, Arena and other stocks were poised to move on above-average volume Friday.
Despite recent setbacks, investors are still searching for a company to unlock a treatment for Alzheimer's disease.
Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics, Inc (TSX: TTH, NASDAQ:TTHI) today announced the results of a Phase 2 placebo-controlled study in 351 patients with mild to moderate Alzheimer’s...
Biopharmaceutical company Transition Therapeutics is set to pay Eli Lilly $1 million to acquire exclusive rights to develop preclinical compounds for diabetes.
Several stocks trading near $5 were moving on above-average volume during Tuesday's session.
Elan is forced to cut high doses of its Alzheimer's drug ELND005 from a mid-stage study, while Seattle Genetics hooks up with a Japanese drug maker.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.